Traditional Chinese Herbal Formula and Its Active Ingredient Loganin Reduce Substance P-Driven Bladder Overactivity in Rats

What the researchers found

Ba-Wei-Di-Huang-Wan (BWDHW) and its active component loganin dose-dependently inhibited reactive oxygen species (H₂O₂ and HOCl) activity in vitro. In rats, oral pretreatment with BWDHW (250 mg/kg) or loganin (5 mg/kg) twice daily for two weeks significantly suppressed substance P-induced increases in voiding frequency, pelvic afferent nerve activity, NF-κB/ICAM-1 expression, leukocyte infiltration (neutrophils, monocytes/macrophages, and mast cells), and reactive oxygen species levels in the bladder.

The protective effects were mediated through inhibition of substance P/neurokinin-1 receptor signaling, which reduced downstream NF-κB activation, ICAM-1-mediated immune cell adhesion, and oxidative tissue injury.

Why it matters

Overactive bladder affects millions of people and current treatments often have significant side effects. This study identifies loganin as a specific active compound that targets the substance P inflammatory cascade — a well-known neuropeptide pathway involved in bladder dysfunction. By showing exactly how loganin interrupts this signaling chain, the research opens a potential path toward more targeted therapies with fewer side effects than current anticholinergic drugs.

How the study worked

Researchers used urethane-anesthetized female Wistar rats and induced bladder hyperactivity by injecting substance P directly into the blood supply. BWDHW and loganin were given orally twice daily for two weeks before testing. Bladder function was measured using cystometry (pressure recordings during filling and voiding), and nerve activity was recorded from the pelvic nerve. Inflammatory markers (NF-κB, ICAM-1) were assessed by Western blot and tissue staining, while oxidative stress was measured using ultrasensitive chemiluminescence. Immune cell infiltration was evaluated with specific stains for neutrophils, monocytes/macrophages, and mast cells.

What this study cannot tell us

This study was conducted entirely in anesthetized rats, which limits direct translation to human bladder conditions experienced during normal activity. The substance P was administered externally rather than released naturally, which may not perfectly mimic the disease process. No human safety or efficacy data were generated, and the two-week treatment period is relatively short. The exact dosing needed for humans remains unknown.

How to read the evidence

This is a preclinical animal study using an established rat model of bladder hyperactivity. While the methodology is rigorous — including electrophysiology, Western blot, and multiple inflammatory markers — the findings have not been tested in humans, placing this at an early stage of evidence.

When this study was published

Published in 2016, this study is about 10 years old. The substance P/NF-κB pathway remains an active area of research, though no human clinical trials of loganin for bladder hyperactivity appear to have followed from this work.

The bigger picture

Substance P is a neuropeptide involved in pain and inflammation throughout the body, not just the bladder. This study adds to growing evidence that targeting neuropeptide signaling pathways — rather than broadly suppressing nerve or muscle activity — could lead to more precise treatments for inflammatory conditions. The identification of loganin as the active compound in a traditional medicine also exemplifies how modern pharmacology can isolate effective molecules from herbal formulas.

Questions still open

• Would loganin show similar protective effects in human overactive bladder patients?
• Could loganin be effective when given after bladder inflammation has already developed, rather than as a preventive pretreatment?
• Does loganin affect substance P signaling in other organ systems where this neuropeptide drives inflammation?

Common questions

Read the original research

Ba-Wei-Di-Huang-Wan through its active ingredient loganin counteracts substance P-enhanced NF-κB/ICAM-1 signaling in rats with bladder hyperactivity.

Neurourology and urodynamics, 35(7), 771-9

Citation

Tsai, Wen-Hsin; Wu, Chung-Hsin; Cheng, Chen-Hung; Chien, Chiang-Ting. (2016). Ba-Wei-Di-Huang-Wan through its active ingredient loganin counteracts substance P-enhanced NF-κB/ICAM-1 signaling in rats with bladder hyperactivity.. Neurourology and urodynamics, 35(7), 771-9. https://doi.org/10.1002/nau.22816